Emergent Expanded Access for ahSC Augmentation of Nerve Autografts After Severe Peripheral Nerve Injury.
Primary Purpose
Sciatic Nerve Injury
Status
No longer available
Phase
Locations
United States
Study Type
Expanded Access
Intervention
Autologous human Schwann cells
Sponsored by
About this trial
This is an expanded access trial for Sciatic Nerve Injury
Eligibility Criteria
Single patient with severe sciatic nerve injury enrolled under emergency request
Sites / Locations
- University of Miami
Outcomes
Primary Outcome Measures
Secondary Outcome Measures
Full Information
NCT ID
NCT02510079
First Posted
July 15, 2015
Last Updated
November 15, 2021
Sponsor
W. Dalton Dietrich
Collaborators
The Miami Project to Cure Paralysis
1. Study Identification
Unique Protocol Identification Number
NCT02510079
Brief Title
Emergent Expanded Access for ahSC Augmentation of Nerve Autografts After Severe Peripheral Nerve Injury.
Official Title
Emergent Expanded Access to Use Autologous Human Schwann Cell Augmentation of Nerve Autograft Repair in a Single Patient With Severe Peripheral Nerve Injury
Study Type
Expanded Access
2. Study Status
Record Verification Date
November 2021
Overall Recruitment Status
No longer available
Study Start Date
undefined (undefined)
Primary Completion Date
undefined (undefined)
Study Completion Date
undefined (undefined)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor-Investigator
Name of the Sponsor
W. Dalton Dietrich
Collaborators
The Miami Project to Cure Paralysis
4. Oversight
5. Study Description
Brief Summary
The primary purpose of this research study is to determine the safety of injecting ones own Schwann cells to augment sural nerve autografts after a severe, non-lacerating injury to the sciatic nerve has occurred.
Detailed Description
The secondary purpose of this research project is to evaluate whether transplanted Schwann cells can enhance recovery of sensory and motor function. Emergency expanded access for a single patient was granted, as the patient was an ideal candidate for sural nerve repair augmented by autologous Schwann cells which could be harvested from a relatively small segment of sensory nerve. The cells were expanded using cell culture techniques and placed along with the sural nerve grafts wrapped by an FDA approved collagen matrix (Duragen). This study is being conducted at the Jackson Memorial and the University of Miami health systems. As a research subject the patient will be in this study for a total of 5 years from the date receiving Schwann cell transplant augmentation of sural nerve autografts.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Sciatic Nerve Injury
7. Study Design
8. Arms, Groups, and Interventions
Intervention Type
Biological
Intervention Name(s)
Autologous human Schwann cells
Intervention Description
Schwann cells harvested from the sural nerve will be autologously transplanted along sural nerve autografts wrapped in a collagen matrix (Duragen).
10. Eligibility
Sex
Female
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
65 Years
Eligibility Criteria
Single patient with severe sciatic nerve injury enrolled under emergency request
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
W. Dalton Dietrich, MD
Organizational Affiliation
University of Miami
Official's Role
Principal Investigator
Facility Information:
Facility Name
University of Miami
City
Miami
State/Province
Florida
ZIP/Postal Code
33136
Country
United States
12. IPD Sharing Statement
Learn more about this trial
Emergent Expanded Access for ahSC Augmentation of Nerve Autografts After Severe Peripheral Nerve Injury.
We'll reach out to this number within 24 hrs